TPP8 is a small molecule antibacterial inhibiting the ATPase of DNA gyrase with IC50 of 0.3 uM, binds and inhibits the ATPase domain of the gyrase B subunit, shows activity against M. abscessus strains with MIC of 0.04-0.2 uM.

TXA707 is the active metabolite of TXA709 and bacterial protein FtsZ inhibitor, maintains potent activity against S. aureus strains (e.g., MRSA, VRSA, DNSSA, and LNSSA) that are resistant to current SOC antibiotics.

TXA709 is a prodrug of FtsZ-targeting benzamide compound (TXA707) with enhanced metabolic stability, demonstrates improved pharmacokinetic properties, and superior in vivo antistaphylococcal efficacy (both oral and intravenous) relative to previously iden

TXY436 is an N-Mannich base derivative and FtsZ-directed prodrug of PC190723, TXY436 is effective against S. aureus can also target Gram-negative bacteria, such as Escherichia coli.

TXY541 is a 1-methylpiperidine-4-carboxamide prodrug of PC190723 and bacterial protein FtsZ inhibitor, TXY541 is efficacious in vivo in mouse models of systemic infection with both methicillin-sensitive and methicillin-resistant S. aureus.

VU0026921 is a small molecule modulator of metal homeostasis in gram-positive pathogens, disrupts metal homeostasis in multiple Gram-positive bacteria, leading to increased reactive oxygen species and cell death.

NPP-669 (NPP669) is an orally bioavailable cidofovir (CDV) analogue and prodrug, has increased lipophilicity, improved oral absorption, reduced nephrotoxicity, increased cellular uptake, and increased activity against several dsDNA viruses compared to CDV

AG-7404 (AG7404) is a potent, irreversible inhibitor of picornaviral 3C protease, exhibits EC50 values of 80-674 nM against a large panel of programmatically important poliovirus strains.

SJW-2C-227 is a broad-spectrum anti-viral compound that target enterovirus 2C potein, inhibits 2C ATPase activity, exhibits anti-viral activity of SJW-2C-227 with an EC50 of 1.7 µM against EVA71 and 0.52 µM against EV-D68.

ZHSI-1 is a novel inhibitor of Enterovirus 71 (EV71) and Coxsackie A16 (CVA16) replication, interacts with 3D and potently inhibits EV71-induced cell death with IC50 of 3.27 uM.

ZHSI-1 hydrochloride is a novel inhibitor of Enterovirus 71 (EV71) and Coxsackie A16 (CVA16) replication, interacts with 3D and potently inhibits EV71-induced cell death with IC50 of 3.27 uM.

Cotransin CT8 (CT-08) is a substrate-selective co-translational translocation inhibitor, binds the Sec61 translocon to inhibit cotranslational translocation of a subset of secreted and type I transmembrane proteins.

Cotransin CT9 (CT-09) is a substrate-selective co-translational translocation inhibitor, binds the Sec61 translocon to inhibit cotranslational translocation of a subset of secreted and type I transmembrane proteins.

PS3061 (PS 3061) is a substrate-selective co-translational translocation inhibitor, modulates SEC61 translocon and inhibits both DENV and ZIKV virion production and replication.

CWHM-974 is a fluphenazine derivative with antifungal activity against Candida albicans, significantly reduces susceptibility to multidrug transporter-mediated resistance.

FC12406 is a highly potent and broadly active antifungal agent, has MIC of 0.2 ug/mL against Candida albicans.

MMV688766 (MMV 688766) is a small molecule displaying broad-spectrum fungicidal activity through perturbation of lipid homeostasis, inhibits the growth of four geographically distinct C. auris clades with MIC80 of 12.5-50 uM.

NP-BTA is a potent, allosteric inhibitor of C. albicans glutaminyl-tRNA synthetase Gln4 with ITC KD of 180 nM and IC50 of 108 nM, strongly inhibits Candida albicans growth.

NPD6433 is a novel broad-spectrum antifungal agent with MIC <10 ug/mL against C. albicans, Candida glabrata, Candida auris, and C. neoformans, inhibits Fas1 enoyl reductase activity.

YU385599 is a high-affinity inhibitor of fungal pantothenate kinase (PanK), exhibits excellent activity against the human pathogens Candida albicans, C. glabrata, and C. parapsilosis.

DF-006 is a small molecule, orally active Alpha-kinase 1 (ALPK1) agonist, activates ALPK1 and stimulates host innate immunity locally in liver, DF-006 enacts potent anti-HBV responses in mouse models of HBV and in primary human hepatocytes.

E-CFCP is a novel long-acting nucleotide reverse transcriptase inhibitor (NRTI) against HBV, shows potent activity against HBV WTD1 and HBV WTC2 with IC50 of 1.8 and 0.7 nM, respectively.